Skip to main content

Research Repository

Advanced Search

What is normal? Next generation sequencing-driven analysis of the human circulating miRNAOme

Tonge, DP; Gant, TW

What is normal? Next generation sequencing-driven analysis of the human circulating miRNAOme Thumbnail


Authors

TW Gant



Abstract

Background
MicroRNAs (miRNAs) are short non-protein-coding RNA species that have a regulatory function in modulating protein translation and degradation of specific mRNAs. MicroRNAs are estimated to target approximately 60 % of all human mRNAs and are associated with the regulation of all physiological processes. Similar to many messenger RNAs (mRNA), miRNAs exhibit marked tissue specificity, and appear to be dysregulated in response to specific pathological conditions. Perhaps, one of the most significant findings is that miRNAs are detectable in various biological fluids and are stable during routine clinical processing, paving the way for their use as novel biomarkers. Despite an increasing number of publications reporting individual miRNAs or miRNA signatures to be diagnostic of disease or indicative of response to therapy, there is still a paucity of baseline data necessary for their validation. To this end, we utilised state of the art sequencing technologies to determine the global expression of all circulating miRNAs within the plasma of 18 disease-free human subjects.

Results
In excess of 500 miRNAs were detected in our study population with expression levels across several orders of magnitude. Ten highly expressed miRNAs accounted for 90 % of the total reads that mapped showing that despite the range of miRNAs present, the total miRNA load of the plasma was predominated by just these few species (50 % of which are blood cell associated). Ranges of expression were determined for all miRNA detected (>500) and a set of highly stable miRNAs identified. Finally, the effects of gender, smoking status and body mass index on miRNA expression were determined.

Conclusions
The data contained within will be of particular use to researchers performing miRNA-based biomarker screening in plasma and allow shortlisting of candidates a priori to expedite discovery or reduce costs as required.

Acceptance Date Feb 1, 2016
Publication Date Feb 9, 2016
Publicly Available Date Mar 28, 2024
Journal BMC Molecular Biology
Publisher Springer Verlag
DOI https://doi.org/10.1186/s12867-016-0057-9
Keywords Plasma sequencing, miRNA, Small RNA, NGS, Biomarker, Baseline
Publisher URL http://dx.doi.org/10.1186/s12867-016-0057-9